Vaxcyte, Inc. $PCVX Holdings Decreased by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. lowered its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 92.1% during the third quarter, Holdings Channel.com reports. The fund owned 92,898 shares of the company’s stock after selling 1,081,982 shares during the period. Nan Fung Trinity HK Ltd.’s holdings in Vaxcyte were worth $5,286,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. New York Life Investment Management LLC boosted its position in Vaxcyte by 19.7% during the third quarter. New York Life Investment Management LLC now owns 21,011 shares of the company’s stock valued at $1,196,000 after purchasing an additional 3,451 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in Vaxcyte by 6.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 7,808 shares of the company’s stock valued at $438,000 after purchasing an additional 444 shares in the last quarter. Candriam S.C.A. increased its position in shares of Vaxcyte by 115.0% during the 3rd quarter. Candriam S.C.A. now owns 447,260 shares of the company’s stock worth $25,542,000 after purchasing an additional 239,206 shares during the last quarter. Covestor Ltd increased its position in shares of Vaxcyte by 31.1% during the 3rd quarter. Covestor Ltd now owns 939 shares of the company’s stock worth $53,000 after purchasing an additional 223 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Vaxcyte during the 3rd quarter worth approximately $1,270,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Stock Performance

Vaxcyte stock opened at $64.69 on Friday. Vaxcyte, Inc. has a 52 week low of $42.40 and a 52 week high of $90.75. The company has a current ratio of 4.56, a quick ratio of 4.56 and a debt-to-equity ratio of 0.04. The stock has a 50-day simple moving average of $62.19 and a 200 day simple moving average of $57.60.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($1.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.11) by $0.12. During the same period last year, the company posted ($1.56) EPS. As a group, sell-side analysts forecast that Vaxcyte, Inc. will post -7.51 earnings per share for the current fiscal year.

Insider Activity at Vaxcyte

In related news, CAO Elvia Cowan sold 19,000 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $86.74, for a total transaction of $1,648,060.00. Following the transaction, the chief accounting officer directly owned 27,860 shares of the company’s stock, valued at approximately $2,416,576.40. The trade was a 40.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jim Wassil sold 18,000 shares of the stock in a transaction on Monday, October 5th. The shares were sold at an average price of $86.74, for a total value of $1,561,320.00. Following the completion of the sale, the executive vice president owned 145,435 shares in the company, valued at approximately $12,615,031.90. This trade represents a 11.01% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 50,692 shares of company stock valued at $4,032,875 over the last quarter. 3.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Guggenheim upped their price objective on Vaxcyte from $116.00 to $125.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. Bank of America decreased their target price on shares of Vaxcyte from $133.00 to $130.00 and set a “buy” rating for the company in a research note on Monday, September 28th. Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Zacks Research upgraded shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Friday, October 2nd. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $110.50.

Vaxcyte Profile

Vaxcyte, Inc. is a clinical-stage biotechnology company developing vaccines to prevent bacterial infectious diseases. Its research focuses on conjugate vaccines, which link bacterial sugars to carrier proteins to help generate an immune response. The company’s pipeline includes VAX-24 and VAX-31, investigational pneumococcal vaccines designed to protect against a broad range of strains, as well as VAX-A1, a candidate targeting Group A Streptococcus. Vaxcyte has no approved commercial vaccines; its programs remain under development.